SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) and its operating unit InnerCool Therapies today announced the launch of InnerCool's newly redesigned website at www.innercool.com. The updated and expanded website highlights InnerCool's new RapidBlue(TM) high-performance endovascular temperature modulation system, its CoolBlue(TM) surface system, and CoolConnect Adapters to allow CoolBlue surface pads to be used with other hypothermia consoles.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
"The new website provides enhanced visual content and a more comprehensive overview of InnerCool's new products. InnerCool is believed to be the only Company in the U.S. and internationally focused on the development of a diverse portfolio of best-in-class temperature modulation therapy products for multiple vertical market opportunities. We have endovascular and surface-based systems, and advanced low-profile, flexible catheters with fully integrated temperature sensors, all of which have FDA 510(k) clearances and CE marks. In addition, in November 2008, we announced the UroCool System, an investigational targeted tissue cooling system that has initially been developed for robotic-assisted and traditional prostate surgeries. This pelvic cooling technology platform has the opportunity to be further expanded into other clinical applications. At the same time, we are working on our CoolFuse System for use in the hospital setting and by emergency medical services (EMS)," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies.
RapidBlue(TM) Endovascular Temperature Modulation System
The RapidBlue System includes a programmable con
'/>"/>
| SOURCE Cardium Therapeutics Copyright©2009 PR Newswire. All rights reserved |